At the second attempt, the FDA has approved Citius Pharmaceuticals' marketing application for Lymphir, a new version of a lymphoma therapy withdrawn from sale several years ago.
The FDA has approved Servier's vorasidenib for two forms of glioma, becoming the first targeted therapy for this aggressive and incurable form of brain cancer.
Ireland-headquartered pharma group Mallinckrodt has agreed to divest its subsidiary Therakos to private equity firm CVC Capital Partners for $925 million, well below the $1.33 billion it pa
Shares in Actinium Pharmaceuticals have lost almost two-thirds of their value after the FDA asked for a second clinical trial before it would consider reviewing the company's Iomab-B radiol
